Marksans Pharma Ltd

Marksans Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Marksans Pharma Ltd

₹ 249 -2.17%
27 May - close price
marksanspharma.com BSE: 524404 NSE: MARKSANS
About

Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products [1]

Key Points

Product Portfolio
OTC Products: (74% of FY24 revenue)
Include Pain Management, Cough and Cold, Digestive Remedies, Vitamins and Tonics, Skin Treatments, and Allergies.[1]
Prescription (Rx) Products: (26%)[2]
Includes cardiovascular, central nervous system (CNS), anti-allergic, anticancer, and anti-diabetic drugs.

Website BSE NSE
  • Market Cap ₹ 11,296 Cr.
  • Current Price ₹ 249
  • High / Low ₹ 271 / 155
  • Stock P/E 27.0
  • Book Value ₹ 66.7
  • Dividend Yield 0.32 %
  • ROCE 18.8 %
  • ROE 15.2 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare Nifty Microcap 250 Nifty Total Market BSE 1000 Nifty Smallcap 500

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
486 500 531 586 560 591 642 682 708 620 720 754 856
376 398 417 453 450 462 495 543 582 520 576 594 661
Operating Profit 110 102 114 133 110 128 147 139 127 100 144 161 195
OPM % 23% 20% 21% 23% 20% 22% 23% 20% 18% 16% 20% 21% 23%
11 10 19 5 17 15 -0 28 15 6 22 20 35
Interest 2 2 2 3 5 3 3 3 3 6 6 6 6
Depreciation 14 14 18 22 21 20 20 21 23 23 27 24 24
Profit before tax 104 97 114 113 100 120 125 143 116 77 133 151 200
Tax % 21% 27% 26% 26% 23% 26% 22% 27% 22% 24% 26% 25% 25%
83 70 84 83 78 89 98 105 91 58 99 114 149
EPS in Rs 1.81 1.52 1.84 1.84 1.73 1.96 2.13 2.31 2.00 1.29 2.17 2.50 3.27
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
797 893 767 913 1,000 1,134 1,376 1,491 1,852 2,177 2,623 2,951
612 757 722 834 868 942 1,037 1,232 1,513 1,719 2,094 2,350
Operating Profit 185 136 45 78 132 192 340 259 340 459 529 601
OPM % 23% 15% 6% 9% 13% 17% 25% 17% 18% 21% 20% 20%
3 9 7 8 5 0 7 42 59 50 70 83
Interest 16 10 7 10 10 9 8 8 9 11 12 24
Depreciation 16 28 30 27 23 27 36 45 52 74 83 99
Profit before tax 156 107 15 50 104 157 302 248 338 424 504 561
Tax % 28% 23% 24% 28% 23% 23% 21% 25% 21% 26% 24% 25%
112 83 11 36 80 121 239 187 265 315 383 420
EPS in Rs 2.67 1.92 0.22 0.80 1.87 2.95 5.76 4.51 5.88 6.92 8.40 9.22
Dividend Payout % 4% 21% 23% 6% 3% 3% 4% 6% 9% 9% 10% 0%
Compounded Sales Growth
10 Years: 13%
5 Years: 16%
3 Years: 17%
TTM: 13%
Compounded Profit Growth
10 Years: 18%
5 Years: 12%
3 Years: 16%
TTM: 10%
Stock Price CAGR
10 Years: 19%
5 Years: 28%
3 Years: 49%
1 Year: 0%
Return on Equity
10 Years: 17%
5 Years: 17%
3 Years: 16%
Last Year: 15%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 41 41 41 41 41 41 41 41 45 45 45 45
Reserves 326 401 392 430 502 595 846 1,161 1,700 2,020 2,422 2,978
101 100 110 118 100 30 34 111 123 244 322 343
207 180 209 142 160 236 307 323 322 372 451 494
Total Liabilities 676 722 752 731 802 902 1,228 1,636 2,190 2,681 3,240 3,861
166 270 267 279 270 303 309 428 486 776 982 1,088
CWIP 0 0 0 0 0 0 12 3 10 9 27 15
Investments 0 0 0 0 0 0 0 0 1 27 1 0
510 452 484 451 533 599 907 1,205 1,694 1,869 2,230 2,758
Total Assets 676 722 752 731 802 902 1,228 1,636 2,190 2,681 3,240 3,861

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
155 31 14 50 27 233 179 99 237 230 207 458
-33 -123 -21 -39 -13 -60 -45 -84 -259 -141 -49 -248
17 -58 -3 3 -21 -114 -15 80 198 -69 -65 -71
Net Cash Flow 138 -150 -10 15 -7 60 118 94 176 21 93 139
Free Cash Flow 118 -101 -14 11 14 174 133 53 184 22 35 329
CFO/OP 108% 43% 31% 73% 41% 134% 67% 66% 88% 77% 63% 100%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 84 89 118 71 64 78 72 97 82 76 75 80
Inventory Days 107 120 151 152 215 155 248 216 192 217 270 278
Days Payable 88 85 129 54 78 71 103 102 91 94 98 96
Cash Conversion Cycle 103 124 140 169 202 163 217 211 183 199 247 261
Working Capital Days 17 59 77 70 97 87 104 121 122 129 142 149
ROCE % 44% 23% 4% 10% 18% 25% 38% 23% 22% 21% 20% 19%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2025
R&D Spend as % of Sales
%

Log in to view insights

Please log in to see hidden values.

Login
Total Manufacturing Capacity
Billion units p.a.
Number of SKUs
Number
ANDA/MA Approved (Cumulative)
Number
Working Capital Cycle
Days
Number of Countries Presence
Number
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
43.85% 43.85% 43.85% 43.85% 43.87% 43.87% 43.87% 43.87% 43.87% 43.87% 43.87% 43.87%
14.90% 15.07% 15.55% 15.57% 18.59% 21.31% 21.95% 22.19% 19.89% 16.92% 8.13% 16.76%
3.65% 4.02% 4.76% 5.17% 3.75% 4.10% 4.30% 4.55% 5.50% 5.28% 5.91% 6.57%
37.60% 37.06% 35.81% 35.40% 33.77% 30.70% 29.88% 29.37% 30.74% 33.93% 42.08% 32.78%
No. of Shareholders 1,88,4472,07,9372,37,3772,54,6992,35,5002,48,8452,59,8132,57,2732,56,2212,65,7882,55,1532,46,279

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls